OTLK Outlook Therapeutics, Inc.
Healthcare$0.40+29.14%ClosedMarket Cap: $16.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
38.27
EV/EBITDA
121287.57
DCF Value
$1.70
FCF Yield
-178574461.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
-370.0%
Operating Margin
-18182.8%
Net Margin
-18297.5%
ROE
0.0%
ROA
-0.0%
ROIC
0.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 null | $127.4K | -41.0% | $-14.0M | $-4.5M | $— | — |
| Q1 null | $-1.2M | 102.5% | $-13.5M | $-23.1M | $— | — |
| Q4 null | $-91.8K | 1098.5% | $-17.3M | $-13.3M | $— | — |
| FY null | $1.4M | 46.5% | $-67.1M | $-62.4M | $— | — |
| Q3 null | $1.5M | 70.8% | $-15.7M | $-20.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-12.4M | $-46.4M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-21.6M | $17.4M | $— | — |
| Q4 null | $170.1K | 50.0% | $-22.9M | $5.7M | $— | — |
| FY null | $0.00 | -Infinity% | $-71.7M | $-75.4M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-19.6M | $44.4M | $— | — |
| Q2 null | $0.00 | -Infinity% | $-18.9M | $-114.3M | $— | — |
| Q1 2024 | $0.00 | -Infinity% | $-10.3M | $-11.2M | $-0.86 | — |